COX-2 and 5-LOX inhibitors can downregulate the progression of colorectal cancer, reducing the capacity for invasion and proliferation in cells of mouse colorectal cancer cell lines (CT26 cells) and human colorectal cancer (HCA7 cells), through supply of the PI3K/AKT pathway35. Here, ALOX5 is linked to colorectal cancer.